Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by TheQQMonon Aug 14, 2020 10:23am
161 Views
Post# 31408104

Continued takeaway - Looking good everyone!

Continued takeaway - Looking good everyone!

What in laymans terms is meant by “composition of matter and method of use patents?

Composition of matter is our novel prodrug R-107.  We own it, it’s ours, nobody else can have it.  Method of use is the way it’s used.  We are pretty much protected by the former but having both is even better. 
[...]

Well I’m not going to put the horse behind the cart here [...]Another aspect of R-107s properties that has me quite excited is that it also interferes with the attachment of palmitate which is a fatty acid on the CV cell that attaches to the spike on the outer surface of coronaviruses. Simply put, by messing with that the coronavirus can’t attach its spike to the membrane of the pulmonary epithelial cells of the lung. When the virus can’t attach itself the cells of the lung, it cant enter and infect the lung cells so yes, it could actually cure COVID or be an essential weapon in the fight.


<< Previous
Bullboard Posts
Next >>